Dara BioSciences grants T3D Therapeutics worldwide rights to commercialize DB959

theflyonthewall.com

Dara BioSciences announced that it has granted T3D Therapeutics the exclusive worldwide rights to develop and commercialize DB959. DB959 is an oral, highly selective, dual nuclear receptor agonist whose primary target is PPARd. DARA had previously developed DB959 through Phase 1 clinical trials for the treatment of diabetes and dyslipidemia.

View Comments